 | |
| Clinical data | |
|---|---|
| Other names | SRX-251; API-251; API251 |
| Routes of administration | Oral[1][2] |
| Drug class | VasopressinV1A receptorantagonist |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C43H48F3N5O5 |
| Molar mass | 771.882 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SRX251, orSRX-251, also known asAPI-251, is aselectivevasopressinV1A receptorantagonist that is or was under development for the treatment ofaggression.[1][3][4][2] It was also being developed for the treatment ofdysmenorrhea, but development for this indication was discontinued.[1] The drug is takenby mouth.[1][2] SRX251 reduces aggressive behavior in rodents.[4][2] It is or was being developed by Azevan Pharmaceuticals.[1][3] In 2007, it was inphase 1clinical trials.[1][3]
AVP is involved in various CNS circuits that underlie many different processes, including those related to the regulation of aggressive behavior, and various studies have used AVP agonists and antagonists to promote or block aggressive behaviors. For example, in resident male hamsters, oral administration of the V1A antagonist SRX251 reduces bite frequencies, and increases attack latencies during resident-intruder testing (Ferris et al. 2006).
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |